Raymond James Financial
GLMD icon

Raymond James Financial’s Galmed Pharmaceuticals GLMD Stock Holding History

Raymond James Financial’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$22 – 5664
2025
Q2 		$22 Buy
+12
New +$18 ﹤0.01% 6920

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Raymond James Financial's GLMD Position: Q3 2025 in Review

Raymond James Financial sold out of Galmed Pharmaceuticals (GLMD) in Q3 2025, closing a stake of 12 shares — an estimated $22 sold.

Raymond James Financial first reported a position in GLMD in Q2 2025 and held it in 1 quarter. The position peaked at $22 in Q2 2025. 14 funds tracked by Wall St. Rank hold GLMD as of Q3 2025.

  • Raymond James Financial reported no remaining Galmed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 12 Galmed Pharmaceuticals shares in Q3 2025, an estimated $22.
  • Raymond James Financial first reported a position in Galmed Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Galmed Pharmaceuticals position peaked at $22 in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.